# Werewolf Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/werewolf-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.werewolftx.com
- Total disclosed funding: $104M
- Latest round: Series B (Dec 23, 2020)
- Investors on record: 13

## About

Werewolf Therapeutics, Inc. is a US-based biotechnology company focused on developing innovative cancer biotherapeutics using their proprietary INDUKINE™ molecules, designed to enhance the immune response against cancer.Founded in 2017 and headquartered in Cambridge, US, Werewolf Therapeutics, Inc. specializes in cancer immunotherapy. The company has engaged in four deals, with its most recent funding round being an IPO on April 29, 2021, raising USD 120 mn. The CEO is Dan Hicklin.Werewolf Therapeutics Inc. specializes in innovative cancer biotherapeutics, primarily through their proprietary INDUKINE™ molecules. These conditionally activated proinflammatory immune modulators enhance the body's immune response against cancer, specifically targeting cancer cells while minimizing effects on healthy tissues. Their customer base includes healthcare providers, oncologists, and research institutions across North America and Europe, aiming to improve treatment outcomes for cancer patients.In 2024, Werewolf Therapeutics reported a revenue of USD 1.885 mn, while their EBITDA for the same year was USD -73.594 mn.Following their IPO on April 29, 2021, where they raised USD 120 mn, Werewolf Therapeutics plans to utilize these funds to advance their INDUKINE™ product candidates, WTX-124 and WTX-330, through phase 1 clinical proof-of-concept studies. The company aims to expand its market presence in the United States and selected European countries as these products progress toward commercialization.

## Funding rounds

- Series B, Dec 23, 2020, $72M — HBM Partners, Adage Capital Management, MPM BioImpact, Longwood Fund, Sphera Fund Management, Deerfield Management, RA Capital Management, Arkin Capital, Taiho Ventures, UPMC Enterprises, Soleus Capital, DC Investment Partners, CaaS Capital Management
- Series A, Aug 2, 2019, $32M — MPM BioImpact, Longwood Fund, Arkin Capital, Taiho Ventures, UPMC Enterprises, DC Investment Partners

## Investors

- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series A, Series B
- Arkin Capital (https://capitalatlas.ai/funds/arkin-capital) — Series A, Series B
- Taiho Ventures (https://capitalatlas.ai/funds/taiho-ventures) — Series A, Series B
- UPMC Enterprises (https://capitalatlas.ai/funds/upmc-enterprises) — Series A, Series B
- DC Investment Partners (https://capitalatlas.ai/funds/dc-investment-partners) — Series A, Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B
- Adage Capital Management — Series B
- Sphera Fund Management — Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series B
- CaaS Capital Management (https://capitalatlas.ai/funds/caas-capital-management) — Series B